Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical
presentations. Parkinson's disease represents a fast-growing neurodegenerative condition; …

The concept of 'idiopathic'Parkinson's disease (PD) as a single entity has been challenged
with the identification of several clinical subtypes, pathogenic genes and putative causative …

Importance Parkinson disease is the most common form of parkinsonism, a group of
neurological disorders with Parkinson disease–like movement problems such as rigidity …

Parkinson's disease (PD) is the second most common neurodegenerative disease
worldwide, and its treatment remains a big challenge. The pathogenesis of PD may be …

INTRODUCTION Parkinson's disease is a debilitating neurological condition affecting more
than 1% of the global population aged 60 and above. The primary medication used to treat …

Objective: The objective of this review was to update evidence‐based medicine
recommendations for treating motor symptoms of Parkinson's disease (PD). Background …

Parkinson's disease is a neurological disorder with evolving layers of complexity. It has long
been characterised by the classical motor features of parkinsonism associated with Lewy …

Abstract Monoamine oxidase-B (MAO-B) inhibitors are commonly used for the symptomatic
treatment of Parkinson's disease (PD). MAO-B inhibitor monotherapy has been shown to be …

Levodopa‐induced dyskinesia is a common complication in Parkinson disease. Pathogenic
mechanisms include phasic stimulation of dopamine receptors, nonphysiological levodopa …